This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
Investors with an interest in Utility - Electric Power stocks have likely encountered both Pattern Energy (PEGI - Free Report) and Vistra Energy Corp. (VST - Free Report) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.
VST.WSA VST GTT VSTE
A California utility is seeking permission to have a company build the world’s largest battery, joining a growing list of power companies investing in storing electricity.
VST.WSA VST VSTE
The portfolio is very concentrated, with St. Joe Companies, Sears Holdings, and its spinoff Seritage Growth Properties forming almost 90% of the entire portfolio.
VST OAK FNMA SHLD FMCKI FMCKJ LUK FNMAS OAK.PRA CLPPZ SRG.PRA JEF FOCIX IPMLF CLPR III FMCCO FMCCP FMCCM FMCCN FMCCI FMCCJ FMCCG FMCKO FMCKP JOE FMCKM FMCKN FMCKK VSTO FMCKL BRS FAAFX VST.WSA SRG T FMCC FAIRX VSTE SHLDW FMCCS FMCCT
Vistra Energy Corp and Dominion Energy Inc – which serve about 5.5 million electricity customers in more than a dozen U.S. states – both say they are done building combined-cycle natural gas-fired power plants.
SCEDN GEC GE SCEDP VST SCE.PRF EXCU SCE VST.WSA SCE.PRD SCE.PRE SCE.PRB VSTE SCE.PRC TRI GNE EXC
LEWIS CENTER, Ohio, May 21, 2018 (GLOBE NEWSWIRE) -- Midwest Energy Emissions Corp. (OTCQB:MEEC) ("ME2C" or the "Company"), a global leader in mercury emissions control for the power industry, has provided its financial results for the first quarter ended March 31, 2018.
VST.WSA VST VSTE CBT MEEC
This article is part of a series that provides an ongoing analysis of the changes made to David Tepper’s 13F portfolio on a quarterly basis. It is based on Appaloosa Management’s regulatory 13F Form filed on 05/15/2018. Please visit our Tracking David Tepper’s Appaloosa Management Portfolio series to get an idea of his investment philosophy and our previous update for the fund’s moves during Q4 2017.
PCG LRCX ETP.PRC KMT CQP CNC VST ALL.PRB ALL.PRC ALL.PRA UAL ALL.PRF ALL.PRG ALL.PRD ALL.PRE NRGEO ALLY.PRA WPZ BSX HCA SYK AABA AMAT SUM UBS.PRDCL CSX BTUUQ CMCSK EEM VNTR BAC QQQ TMUSP TMUS LNG OC NRG BABA ALL ETP CZR GOOGL WMIH MHK TERP WFCNP MGM FB PAH AY TMO ETE CCV WDC WFC.PRL CCZ WFC.PRJ GOOG NVDA BAC WFC.PRT WFC.PRR HUN WFC.PRQ WFC.PRP AGN WFC.PRO UBS WFC.PRN AAPL WFC.PRY WFC.PRX WFC.PRW WFC.PRV LUV WFC WFC.WS WMIHP GJT XPO KNX CMCSA BTU VST.WSA BTU.PR ALLY MU CCV.CL VSTE URI DG UNH ULSGF BYD
This article is part of a series that provides an ongoing analysis of the changes made to John Paulson's 13F stock portfolio on a quarterly basis. It is based on Paulson's regulatory 13F Form filed on 05/15/2018. Please visit our Tracking John Paulson's Paulson & Co. Portfolio series to get an idea of his investment philosophy and our previous update for the fund's moves during Q4 2017.
SNI BGX DISCB VST DISCA TSU TWX AU DISCK ENL BGLF STAY SHPG VIAB HAWK AABA DST OSG.WI SSNC AEM INSW AGG SYMX AET DISC FOX TMUSP TMUS RGORF VRX BKD UTX GOLD BX 2840 TWC OGISD NSW OGSRW MDT BGB SGYP SES CZR OGSWW OGISZ XLGLF SCMP QCOM INSW.WI FOXA OGSBW ENDP NMRK NXPI XL CTL RRS GLD AULGF OSG VRX MYL AGN ODP EGN MON SGYPW HZNP OSGB DISH OVSPW CACQ COL GOLD OVSPA VST.WSA OAS T OVSPD VSTE MNK THM
Welcome to the Vistra Energy First Quarter 2018 Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks, there will be a question-and-answer session. [Operator Instructions]
VST.WSA VST VSTE
Frontier Communications Corporation (FTR - Free Report) reported a narrower-than-expected loss in first-quarter 2018. Top- and Bottom-Line Results Frontier Communications reported an adjusted loss of 58 cents per share in the first quarter. The reported figure was narrower than the Zacks Consensus Estimate of a loss of 83 cents. It also came in narrower than the loss of $1.20 per share posted in the year-ago quarter.
WFCNP GXPPP VST WFC.PRL WFC.PRJ GXP WFC.PRT AMRC WFC.PRR WFC.PRQ FTRPR WFC.PRP WFC.PRO WFC.PRN WFC.PRY WFC.PRX WFC.PRW WFC.PRV WFC WFC.WS GXP.PRB GXP.PRF VST.WSA VSTE FTR GXPPL
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET